Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Cardiology, North Zealand Hospital, Hillerød Hospital, Hillerød, Denmark; Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.
Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Cardiology, North Zealand Hospital, Hillerød Hospital, Hillerød, Denmark.
Ophthalmology. 2024 Sep;131(9):1056-1063. doi: 10.1016/j.ophtha.2024.03.004. Epub 2024 Mar 13.
To examine the association between glucagon-like peptide-1 receptor agonist (GLP-1RA) use and the development of glaucoma in individuals with type 2 diabetes.
Nationwide, nested case-control study.
From a nationwide cohort of 264 708 individuals, we identified 1737 incident glaucoma cases and matched them to 8685 glaucoma-free controls, all aged more than 21 years and treated with metformin and a second-line antihyperglycemic drug formulation, with no history of glaucoma, eye trauma, or eye surgery.
Cases were incidence-density-matched to 5 controls by birth year, sex, and date of second-line treatment initiation.
Conditional logistic regression was used to calculate adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) for glaucoma, defined by first-time diagnosis, first-time use of glaucoma-specific medication, or first-time glaucoma-specific surgical intervention.
Compared with the reference group, who received treatments other than GLP-1RA, individuals who were exposed to GLP-1RA treatment exhibited a lower risk of incident glaucoma (HR, 0.81; CI, 0.70-0.94; P = 0.006). Prolonged treatment extending beyond 3 years lowered the risk even further (HR, 0.71; CI, 0.55-0.91; P = 0.007). Treatment with GLP-1RA for 0 to 1 year (HR, 0.89; CI, 0.70-1.14; P = 0.35) and 1 to 3 years (HR, 0.85; CI, 0.67-1.06; P = 0.15) was not significant.
Exposure to GLP-1RA was associated with a lower risk of developing glaucoma compared with receiving other second-line antihyperglycemic medication.
FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.
研究 2 型糖尿病患者使用胰高血糖素样肽-1 受体激动剂 (GLP-1RA) 与青光眼发展之间的关系。
全国性巢式病例对照研究。
我们从一个全国性的队列中纳入了 264708 名患者，共识别出 1737 例新发青光眼病例，并将其与 8685 例无青光眼的对照组相匹配，所有患者年龄均大于 21 岁，且接受二甲双胍和二线抗高血糖药物治疗，无青光眼、眼外伤或眼部手术史。
通过出生年份、性别和二线治疗开始日期，按病例密度对病例进行 5 对 1 匹配对照。
采用条件逻辑回归计算调整后的比值比（HR）及其 95%置信区间（CI），用于定义首次诊断、首次使用青光眼特异性药物或首次接受青光眼特异性手术干预的青光眼。
与接受 GLP-1RA 以外治疗的参考组相比，接受 GLP-1RA 治疗的患者发生新发青光眼的风险较低（HR，0.81；95%CI，0.70-0.94；P=0.006）。治疗时间超过 3 年进一步降低了风险（HR，0.71；95%CI，0.55-0.91；P=0.007）。治疗 0-1 年（HR，0.89；95%CI，0.70-1.14；P=0.35）和 1-3 年（HR，0.85；95%CI，0.67-1.06；P=0.15）的治疗效果不显著。
与接受其他二线抗高血糖药物治疗相比，暴露于 GLP-1RA 与发生青光眼的风险较低相关。
参考文献后可能会发现专有或商业披露信息。
Zotero 插件